PD‐1 ligand (PD‐L1) is a transmembrane protein, frequently overexpressed in the surface of tumor cells.[3] It has been reported that blocking PD‐1/PD‐L1 interaction can promote tumor recognition and targeting by activated T cells and enhance antitumor immunity, thus being widely used in clinic.[4, 5, 6] Anti‐PD‐1 blocks the PD‐1/PD‐L1 pathway, activates cytotoxic T cells, and stimulates immune response. Here, CD274 is linked to neoplasm.